Neuphoria Therapeutics Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Spyridon Papapetropoulos
- Full Time Employees
- 8
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 100 Summit Dr Burlington MA United States of America 01803
- IPO Date
- Dec 16, 2021
- CIK
- 0001191070
- Website
- neuphoriatx.com
- Similar Companies
- Business
- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) is a clinical-stage biopharmaceutical company that discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders, including neuropsychiatric conditions such as social anxiety disorder and post-traumatic stress disorder; its lead product candidate, BNC210, comprises an oral, proprietary, selective negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor designed for acute as-needed treatment of social anxiety disorder, chronic treatment of post-traumatic stress disorder, and other anxiety-related disorders, having received FDA Fast Track designation and recently completing target enrollment in a Phase 3 trial; additional pipeline assets include alpha-7 nicotinic acetylcholine receptor positive allosteric modulators such as MK-1167 advanced by partner Merck & Co. Inc. in a Phase 2 trial for Alzheimer's disease-related cognitive impairment, alongside legacy programs like BNC101, a monoclonal antibody targeting cancer stem cells in partnership with Carina Biotech. Founded in 2024 and headquartered at 100 Summit Drive in Burlington, Massachusetts, the company operates primarily from the United States with a global focus on high unmet needs in neuropsychiatric and cognitive therapies, reporting eight employees and revenue of US$15.65 million in its latest trailing twelve months. Recent developments encompass a strategic collaboration with Merck & Co. Inc. providing up to $450 million in milestone payments plus royalties, triggered by a $15 million payment in early 2025 upon Phase 2 initiation of MK-1167; a A$1 million milestone from Carina Biotech in November 2024 with potential for A$117 million more; completion of Phase 3 enrollment for BNC210 in September 2025; initiation of a formal strategic review in November 2025 following a Phase 3 setback, evaluating partnerships, licensing, joint ventures, or mergers and acquisitions; and an unsolicited cash takeover offer from Lynx1 Master Fund LP, revised to $4.75 per share as of December 2025.
Company News
Are CBZ, SAFT, NEUP, TCBK Obtaining Fair Deals for their Shareholders?
The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—NRIM, NEUP, SAFT, and RMAX
Are CBZ, SAFT, NEUP Obtaining Fair Deals for their Shareholders?
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—PBCO, NEUP, SAFT, and PFLC
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP)
NEUP Stock Alert: Halper Sadeh LLC is Investigating Whether Neuphoria Therapeutics Inc. is Obtaining a Fair Price for its Shareholders
NEUP Stock Alert: Halper Sadeh LLC is Investigating Whether Neuphoria Therapeutics Inc. is Obtaining a Fair Price for its Shareholders
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP)
Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc
Critical Analysis: Immunic (NASDAQ:IMUX) and Neuphoria Therapeutics (NASDAQ:NEUP)
Contrasting Neuphoria Therapeutics (NASDAQ:NEUP) & Prenetics Global (NASDAQ:PRE)
Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees
Neuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and Premium
Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions
Neuphoria Therapeutics Inc. Sends Letter to Stockholders
Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value
Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process
PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder